0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Topoisomerase Inhibitors Market Research Report 2024
Published Date: May 2024
|
Report Code: QYRE-Auto-12O17372
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Topoisomerase Inhibitors Market Research Report 2024
BUY CHAPTERS

Global Topoisomerase Inhibitors Market Research Report 2024

Code: QYRE-Auto-12O17372
Report
May 2024
Pages:107
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Topoisomerase Inhibitors Market

Topoisomerase inhibitors are a new class of therapeutic drugs whose mechanism of action is to bind to the DNA-topoisomerase complex, causing DNA double-strand breaks and ultimately leading to cell apoptosis. As an ADC payload, topoisomerase is an alternative to the tubulin inhibitors widely used in ADCs in clinical trials.
The global Topoisomerase Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Topoisomerase Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Topoisomerase Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Topoisomerase Inhibitors include Roche, Mundipharma, Purdue Pharma, Debiopharm, Ipsen Pharma, TopoGEN, Novartis, Hikma Pharmaceuticals, Viatris, Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Topoisomerase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Topoisomerase Inhibitors.
The Topoisomerase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Topoisomerase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Topoisomerase Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Topoisomerase Inhibitors Market Report

Report Metric Details
Report Name Topoisomerase Inhibitors Market
Segment by Type
  • Etoposide
  • Irinotecan
  • Topotecan
  • Other
Segment by Application
  • Hospital
  • Clinic
  • Home Care
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche, Mundipharma, Purdue Pharma, Debiopharm, Ipsen Pharma, TopoGEN, Novartis, Hikma Pharmaceuticals, Viatris, Pfizer, Merrimack Pharmaceuticals, Amgen, Johnson & Johnson, BioMérieux, Promega, Takeda Pharmaceutical, Merck KGaA, Cipla, Teva Pharmaceuticals Indutries
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Topoisomerase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Topoisomerase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Topoisomerase Inhibitors Market report?

Ans: The main players in the Topoisomerase Inhibitors Market are Roche, Mundipharma, Purdue Pharma, Debiopharm, Ipsen Pharma, TopoGEN, Novartis, Hikma Pharmaceuticals, Viatris, Pfizer, Merrimack Pharmaceuticals, Amgen, Johnson & Johnson, BioMérieux, Promega, Takeda Pharmaceutical, Merck KGaA, Cipla, Teva Pharmaceuticals Indutries

What are the Application segmentation covered in the Topoisomerase Inhibitors Market report?

Ans: The Applications covered in the Topoisomerase Inhibitors Market report are Hospital, Clinic, Home Care

What are the Type segmentation covered in the Topoisomerase Inhibitors Market report?

Ans: The Types covered in the Topoisomerase Inhibitors Market report are Etoposide, Irinotecan, Topotecan, Other

1 Topoisomerase Inhibitors Market Overview
1.1 Product Definition
1.2 Topoisomerase Inhibitors by Type
1.2.1 Global Topoisomerase Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 Etoposide
1.2.3 Irinotecan
1.2.4 Topotecan
1.2.5 Other
1.3 Topoisomerase Inhibitors by Application
1.3.1 Global Topoisomerase Inhibitors Market Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Home Care
1.4 Global Topoisomerase Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Topoisomerase Inhibitors Revenue 2019-2030
1.4.2 Global Topoisomerase Inhibitors Sales 2019-2030
1.4.3 Global Topoisomerase Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Topoisomerase Inhibitors Market Competition by Manufacturers
2.1 Global Topoisomerase Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global Topoisomerase Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Topoisomerase Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Topoisomerase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Topoisomerase Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Topoisomerase Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of Topoisomerase Inhibitors, Date of Enter into This Industry
2.8 Global Topoisomerase Inhibitors Market Competitive Situation and Trends
2.8.1 Global Topoisomerase Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Topoisomerase Inhibitors Players Market Share by Revenue
2.8.3 Global Topoisomerase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Topoisomerase Inhibitors Market Scenario by Region
3.1 Global Topoisomerase Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Topoisomerase Inhibitors Sales by Region: 2019-2030
3.2.1 Global Topoisomerase Inhibitors Sales by Region: 2019-2024
3.2.2 Global Topoisomerase Inhibitors Sales by Region: 2025-2030
3.3 Global Topoisomerase Inhibitors Revenue by Region: 2019-2030
3.3.1 Global Topoisomerase Inhibitors Revenue by Region: 2019-2024
3.3.2 Global Topoisomerase Inhibitors Revenue by Region: 2025-2030
3.4 North America Topoisomerase Inhibitors Market Facts & Figures by Country
3.4.1 North America Topoisomerase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Topoisomerase Inhibitors Sales by Country (2019-2030)
3.4.3 North America Topoisomerase Inhibitors Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Topoisomerase Inhibitors Market Facts & Figures by Country
3.5.1 Europe Topoisomerase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Topoisomerase Inhibitors Sales by Country (2019-2030)
3.5.3 Europe Topoisomerase Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Topoisomerase Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Topoisomerase Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Topoisomerase Inhibitors Sales by Region (2019-2030)
3.6.3 Asia Pacific Topoisomerase Inhibitors Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Topoisomerase Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Topoisomerase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Topoisomerase Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America Topoisomerase Inhibitors Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Topoisomerase Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Topoisomerase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Topoisomerase Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa Topoisomerase Inhibitors Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Topoisomerase Inhibitors Sales by Type (2019-2030)
4.1.1 Global Topoisomerase Inhibitors Sales by Type (2019-2024)
4.1.2 Global Topoisomerase Inhibitors Sales by Type (2025-2030)
4.1.3 Global Topoisomerase Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global Topoisomerase Inhibitors Revenue by Type (2019-2030)
4.2.1 Global Topoisomerase Inhibitors Revenue by Type (2019-2024)
4.2.2 Global Topoisomerase Inhibitors Revenue by Type (2025-2030)
4.2.3 Global Topoisomerase Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global Topoisomerase Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global Topoisomerase Inhibitors Sales by Application (2019-2030)
5.1.1 Global Topoisomerase Inhibitors Sales by Application (2019-2024)
5.1.2 Global Topoisomerase Inhibitors Sales by Application (2025-2030)
5.1.3 Global Topoisomerase Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global Topoisomerase Inhibitors Revenue by Application (2019-2030)
5.2.1 Global Topoisomerase Inhibitors Revenue by Application (2019-2024)
5.2.2 Global Topoisomerase Inhibitors Revenue by Application (2025-2030)
5.2.3 Global Topoisomerase Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global Topoisomerase Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Topoisomerase Inhibitors Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Mundipharma
6.2.1 Mundipharma Company Information
6.2.2 Mundipharma Description and Business Overview
6.2.3 Mundipharma Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Mundipharma Topoisomerase Inhibitors Product Portfolio
6.2.5 Mundipharma Recent Developments/Updates
6.3 Purdue Pharma
6.3.1 Purdue Pharma Company Information
6.3.2 Purdue Pharma Description and Business Overview
6.3.3 Purdue Pharma Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Purdue Pharma Topoisomerase Inhibitors Product Portfolio
6.3.5 Purdue Pharma Recent Developments/Updates
6.4 Debiopharm
6.4.1 Debiopharm Company Information
6.4.2 Debiopharm Description and Business Overview
6.4.3 Debiopharm Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Debiopharm Topoisomerase Inhibitors Product Portfolio
6.4.5 Debiopharm Recent Developments/Updates
6.5 Ipsen Pharma
6.5.1 Ipsen Pharma Company Information
6.5.2 Ipsen Pharma Description and Business Overview
6.5.3 Ipsen Pharma Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Ipsen Pharma Topoisomerase Inhibitors Product Portfolio
6.5.5 Ipsen Pharma Recent Developments/Updates
6.6 TopoGEN
6.6.1 TopoGEN Company Information
6.6.2 TopoGEN Description and Business Overview
6.6.3 TopoGEN Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 TopoGEN Topoisomerase Inhibitors Product Portfolio
6.6.5 TopoGEN Recent Developments/Updates
6.7 Novartis
6.7.1 Novartis Company Information
6.7.2 Novartis Description and Business Overview
6.7.3 Novartis Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Novartis Topoisomerase Inhibitors Product Portfolio
6.7.5 Novartis Recent Developments/Updates
6.8 Hikma Pharmaceuticals
6.8.1 Hikma Pharmaceuticals Company Information
6.8.2 Hikma Pharmaceuticals Description and Business Overview
6.8.3 Hikma Pharmaceuticals Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hikma Pharmaceuticals Topoisomerase Inhibitors Product Portfolio
6.8.5 Hikma Pharmaceuticals Recent Developments/Updates
6.9 Viatris
6.9.1 Viatris Company Information
6.9.2 Viatris Description and Business Overview
6.9.3 Viatris Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Viatris Topoisomerase Inhibitors Product Portfolio
6.9.5 Viatris Recent Developments/Updates
6.10 Pfizer
6.10.1 Pfizer Company Information
6.10.2 Pfizer Description and Business Overview
6.10.3 Pfizer Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Pfizer Topoisomerase Inhibitors Product Portfolio
6.10.5 Pfizer Recent Developments/Updates
6.11 Merrimack Pharmaceuticals
6.11.1 Merrimack Pharmaceuticals Company Information
6.11.2 Merrimack Pharmaceuticals Description and Business Overview
6.11.3 Merrimack Pharmaceuticals Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Merrimack Pharmaceuticals Topoisomerase Inhibitors Product Portfolio
6.11.5 Merrimack Pharmaceuticals Recent Developments/Updates
6.12 Amgen
6.12.1 Amgen Company Information
6.12.2 Amgen Description and Business Overview
6.12.3 Amgen Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Amgen Topoisomerase Inhibitors Product Portfolio
6.12.5 Amgen Recent Developments/Updates
6.13 Johnson & Johnson
6.13.1 Johnson & Johnson Company Information
6.13.2 Johnson & Johnson Description and Business Overview
6.13.3 Johnson & Johnson Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Johnson & Johnson Topoisomerase Inhibitors Product Portfolio
6.13.5 Johnson & Johnson Recent Developments/Updates
6.14 BioMérieux
6.14.1 BioMérieux Company Information
6.14.2 BioMérieux Description and Business Overview
6.14.3 BioMérieux Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.14.4 BioMérieux Topoisomerase Inhibitors Product Portfolio
6.14.5 BioMérieux Recent Developments/Updates
6.15 Promega
6.15.1 Promega Company Information
6.15.2 Promega Description and Business Overview
6.15.3 Promega Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Promega Topoisomerase Inhibitors Product Portfolio
6.15.5 Promega Recent Developments/Updates
6.16 Takeda Pharmaceutical
6.16.1 Takeda Pharmaceutical Company Information
6.16.2 Takeda Pharmaceutical Description and Business Overview
6.16.3 Takeda Pharmaceutical Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Takeda Pharmaceutical Topoisomerase Inhibitors Product Portfolio
6.16.5 Takeda Pharmaceutical Recent Developments/Updates
6.17 Merck KGaA
6.17.1 Merck KGaA Company Information
6.17.2 Merck KGaA Description and Business Overview
6.17.3 Merck KGaA Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Merck KGaA Topoisomerase Inhibitors Product Portfolio
6.17.5 Merck KGaA Recent Developments/Updates
6.18 Cipla
6.18.1 Cipla Company Information
6.18.2 Cipla Description and Business Overview
6.18.3 Cipla Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Cipla Topoisomerase Inhibitors Product Portfolio
6.18.5 Cipla Recent Developments/Updates
6.19 Teva Pharmaceuticals Indutries
6.19.1 Teva Pharmaceuticals Indutries Company Information
6.19.2 Teva Pharmaceuticals Indutries Description and Business Overview
6.19.3 Teva Pharmaceuticals Indutries Topoisomerase Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Teva Pharmaceuticals Indutries Topoisomerase Inhibitors Product Portfolio
6.19.5 Teva Pharmaceuticals Indutries Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Topoisomerase Inhibitors Industry Chain Analysis
7.2 Topoisomerase Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Topoisomerase Inhibitors Production Mode & Process
7.4 Topoisomerase Inhibitors Sales and Marketing
7.4.1 Topoisomerase Inhibitors Sales Channels
7.4.2 Topoisomerase Inhibitors Distributors
7.5 Topoisomerase Inhibitors Customers
8 Topoisomerase Inhibitors Market Dynamics
8.1 Topoisomerase Inhibitors Industry Trends
8.2 Topoisomerase Inhibitors Market Drivers
8.3 Topoisomerase Inhibitors Market Challenges
8.4 Topoisomerase Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Topoisomerase Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Topoisomerase Inhibitors Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Topoisomerase Inhibitors Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Topoisomerase Inhibitors Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Topoisomerase Inhibitors Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Topoisomerase Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Topoisomerase Inhibitors Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Topoisomerase Inhibitors Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Topoisomerase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Topoisomerase Inhibitors, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Topoisomerase Inhibitors, Product Type & Application
 Table 12. Global Key Manufacturers of Topoisomerase Inhibitors, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Topoisomerase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Topoisomerase Inhibitors as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Topoisomerase Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Topoisomerase Inhibitors Sales by Region (2019-2024) & (K Units)
 Table 18. Global Topoisomerase Inhibitors Sales Market Share by Region (2019-2024)
 Table 19. Global Topoisomerase Inhibitors Sales by Region (2025-2030) & (K Units)
 Table 20. Global Topoisomerase Inhibitors Sales Market Share by Region (2025-2030)
 Table 21. Global Topoisomerase Inhibitors Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Topoisomerase Inhibitors Revenue Market Share by Region (2019-2024)
 Table 23. Global Topoisomerase Inhibitors Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Topoisomerase Inhibitors Revenue Market Share by Region (2025-2030)
 Table 25. North America Topoisomerase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Topoisomerase Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 27. North America Topoisomerase Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 28. North America Topoisomerase Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Topoisomerase Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Topoisomerase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Topoisomerase Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Topoisomerase Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Topoisomerase Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Topoisomerase Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Topoisomerase Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Topoisomerase Inhibitors Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Topoisomerase Inhibitors Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Topoisomerase Inhibitors Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Topoisomerase Inhibitors Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Topoisomerase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Topoisomerase Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Topoisomerase Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Topoisomerase Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Topoisomerase Inhibitors Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Topoisomerase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Topoisomerase Inhibitors Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Topoisomerase Inhibitors Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Topoisomerase Inhibitors Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Topoisomerase Inhibitors Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Topoisomerase Inhibitors Sales (K Units) by Type (2019-2024)
 Table 51. Global Topoisomerase Inhibitors Sales (K Units) by Type (2025-2030)
 Table 52. Global Topoisomerase Inhibitors Sales Market Share by Type (2019-2024)
 Table 53. Global Topoisomerase Inhibitors Sales Market Share by Type (2025-2030)
 Table 54. Global Topoisomerase Inhibitors Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Topoisomerase Inhibitors Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Topoisomerase Inhibitors Revenue Market Share by Type (2019-2024)
 Table 57. Global Topoisomerase Inhibitors Revenue Market Share by Type (2025-2030)
 Table 58. Global Topoisomerase Inhibitors Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Topoisomerase Inhibitors Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Topoisomerase Inhibitors Sales (K Units) by Application (2019-2024)
 Table 61. Global Topoisomerase Inhibitors Sales (K Units) by Application (2025-2030)
 Table 62. Global Topoisomerase Inhibitors Sales Market Share by Application (2019-2024)
 Table 63. Global Topoisomerase Inhibitors Sales Market Share by Application (2025-2030)
 Table 64. Global Topoisomerase Inhibitors Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Topoisomerase Inhibitors Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Topoisomerase Inhibitors Revenue Market Share by Application (2019-2024)
 Table 67. Global Topoisomerase Inhibitors Revenue Market Share by Application (2025-2030)
 Table 68. Global Topoisomerase Inhibitors Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Topoisomerase Inhibitors Price (US$/Unit) by Application (2025-2030)
 Table 70. Roche Company Information
 Table 71. Roche Description and Business Overview
 Table 72. Roche Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Roche Topoisomerase Inhibitors Product
 Table 74. Roche Recent Developments/Updates
 Table 75. Mundipharma Company Information
 Table 76. Mundipharma Description and Business Overview
 Table 77. Mundipharma Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Mundipharma Topoisomerase Inhibitors Product
 Table 79. Mundipharma Recent Developments/Updates
 Table 80. Purdue Pharma Company Information
 Table 81. Purdue Pharma Description and Business Overview
 Table 82. Purdue Pharma Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Purdue Pharma Topoisomerase Inhibitors Product
 Table 84. Purdue Pharma Recent Developments/Updates
 Table 85. Debiopharm Company Information
 Table 86. Debiopharm Description and Business Overview
 Table 87. Debiopharm Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Debiopharm Topoisomerase Inhibitors Product
 Table 89. Debiopharm Recent Developments/Updates
 Table 90. Ipsen Pharma Company Information
 Table 91. Ipsen Pharma Description and Business Overview
 Table 92. Ipsen Pharma Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Ipsen Pharma Topoisomerase Inhibitors Product
 Table 94. Ipsen Pharma Recent Developments/Updates
 Table 95. TopoGEN Company Information
 Table 96. TopoGEN Description and Business Overview
 Table 97. TopoGEN Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. TopoGEN Topoisomerase Inhibitors Product
 Table 99. TopoGEN Recent Developments/Updates
 Table 100. Novartis Company Information
 Table 101. Novartis Description and Business Overview
 Table 102. Novartis Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Novartis Topoisomerase Inhibitors Product
 Table 104. Novartis Recent Developments/Updates
 Table 105. Hikma Pharmaceuticals Company Information
 Table 106. Hikma Pharmaceuticals Description and Business Overview
 Table 107. Hikma Pharmaceuticals Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Hikma Pharmaceuticals Topoisomerase Inhibitors Product
 Table 109. Hikma Pharmaceuticals Recent Developments/Updates
 Table 110. Viatris Company Information
 Table 111. Viatris Description and Business Overview
 Table 112. Viatris Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Viatris Topoisomerase Inhibitors Product
 Table 114. Viatris Recent Developments/Updates
 Table 115. Pfizer Company Information
 Table 116. Pfizer Description and Business Overview
 Table 117. Pfizer Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Pfizer Topoisomerase Inhibitors Product
 Table 119. Pfizer Recent Developments/Updates
 Table 120. Merrimack Pharmaceuticals Company Information
 Table 121. Merrimack Pharmaceuticals Description and Business Overview
 Table 122. Merrimack Pharmaceuticals Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Merrimack Pharmaceuticals Topoisomerase Inhibitors Product
 Table 124. Merrimack Pharmaceuticals Recent Developments/Updates
 Table 125. Amgen Company Information
 Table 126. Amgen Description and Business Overview
 Table 127. Amgen Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. Amgen Topoisomerase Inhibitors Product
 Table 129. Amgen Recent Developments/Updates
 Table 130. Johnson & Johnson Company Information
 Table 131. Johnson & Johnson Description and Business Overview
 Table 132. Johnson & Johnson Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. Johnson & Johnson Topoisomerase Inhibitors Product
 Table 134. Johnson & Johnson Recent Developments/Updates
 Table 135. BioMérieux Company Information
 Table 136. BioMérieux Description and Business Overview
 Table 137. BioMérieux Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 138. BioMérieux Topoisomerase Inhibitors Product
 Table 139. BioMérieux Recent Developments/Updates
 Table 140. Promega Company Information
 Table 141. Promega Description and Business Overview
 Table 142. Promega Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 143. Promega Topoisomerase Inhibitors Product
 Table 144. Promega Recent Developments/Updates
 Table 145. Takeda Pharmaceutical Company Information
 Table 146. Takeda Pharmaceutical Description and Business Overview
 Table 147. Takeda Pharmaceutical Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 148. Takeda Pharmaceutical Topoisomerase Inhibitors Product
 Table 149. Takeda Pharmaceutical Recent Developments/Updates
 Table 150. Merck KGaA Company Information
 Table 151. Merck KGaA Description and Business Overview
 Table 152. Merck KGaA Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 153. Merck KGaA Topoisomerase Inhibitors Product
 Table 154. Merck KGaA Recent Developments/Updates
 Table 155. Cipla Company Information
 Table 156. Cipla Description and Business Overview
 Table 157. Cipla Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 158. Cipla Topoisomerase Inhibitors Product
 Table 159. Cipla Recent Developments/Updates
 Table 160. Teva Pharmaceuticals Indutries Company Information
 Table 161. Teva Pharmaceuticals Indutries Description and Business Overview
 Table 162. Teva Pharmaceuticals Indutries Topoisomerase Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 163. Teva Pharmaceuticals Indutries Topoisomerase Inhibitors Product
 Table 164. Teva Pharmaceuticals Indutries Recent Developments/Updates
 Table 165. Key Raw Materials Lists
 Table 166. Raw Materials Key Suppliers Lists
 Table 167. Topoisomerase Inhibitors Distributors List
 Table 168. Topoisomerase Inhibitors Customers List
 Table 169. Topoisomerase Inhibitors Market Trends
 Table 170. Topoisomerase Inhibitors Market Drivers
 Table 171. Topoisomerase Inhibitors Market Challenges
 Table 172. Topoisomerase Inhibitors Market Restraints
 Table 173. Research Programs/Design for This Report
 Table 174. Key Data Information from Secondary Sources
 Table 175. Key Data Information from Primary Sources
 Table 176. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Topoisomerase Inhibitors
 Figure 2. Global Topoisomerase Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Topoisomerase Inhibitors Market Share by Type: 2023 & 2030
 Figure 4. Etoposide Product Picture
 Figure 5. Irinotecan Product Picture
 Figure 6. Topotecan Product Picture
 Figure 7. Other Product Picture
 Figure 8. Global Topoisomerase Inhibitors Market Value by Application (2024-2030) & (US$ Million)
 Figure 9. Global Topoisomerase Inhibitors Market Share by Application: 2023 & 2030
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Home Care
 Figure 13. Global Topoisomerase Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 14. Global Topoisomerase Inhibitors Market Size (2019-2030) & (US$ Million)
 Figure 15. Global Topoisomerase Inhibitors Sales (2019-2030) & (K Units)
 Figure 16. Global Topoisomerase Inhibitors Average Price (US$/Unit) & (2019-2030)
 Figure 17. Topoisomerase Inhibitors Report Years Considered
 Figure 18. Topoisomerase Inhibitors Sales Share by Manufacturers in 2023
 Figure 19. Global Topoisomerase Inhibitors Revenue Share by Manufacturers in 2023
 Figure 20. Global 5 and 10 Largest Topoisomerase Inhibitors Players: Market Share by Revenue in Topoisomerase Inhibitors in 2023
 Figure 21. Topoisomerase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 22. Global Topoisomerase Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 23. North America Topoisomerase Inhibitors Sales Market Share by Country (2019-2030)
 Figure 24. North America Topoisomerase Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 25. United States Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 26. Canada Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 27. Europe Topoisomerase Inhibitors Sales Market Share by Country (2019-2030)
 Figure 28. Europe Topoisomerase Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 29. Germany Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. France Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. U.K. Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Italy Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Russia Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. Asia Pacific Topoisomerase Inhibitors Sales Market Share by Region (2019-2030)
 Figure 35. Asia Pacific Topoisomerase Inhibitors Revenue Market Share by Region (2019-2030)
 Figure 36. China Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. Japan Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. South Korea Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. India Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Australia Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. China Taiwan Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Southeast Asia Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Latin America Topoisomerase Inhibitors Sales Market Share by Country (2019-2030)
 Figure 44. Mexico Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Brazil Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Argentina Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Colombia Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Middle East and Africa Topoisomerase Inhibitors Sales Market Share by Country (2019-2030)
 Figure 49. Middle East and Africa Topoisomerase Inhibitors Revenue Market Share by Country (2019-2030)
 Figure 50. Turkey Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Saudi Arabia Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. UAE Topoisomerase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 53. Global Sales Market Share of Topoisomerase Inhibitors by Type (2019-2030)
 Figure 54. Global Revenue Market Share of Topoisomerase Inhibitors by Type (2019-2030)
 Figure 55. Global Topoisomerase Inhibitors Price (US$/Unit) by Type (2019-2030)
 Figure 56. Global Sales Market Share of Topoisomerase Inhibitors by Application (2019-2030)
 Figure 57. Global Revenue Market Share of Topoisomerase Inhibitors by Application (2019-2030)
 Figure 58. Global Topoisomerase Inhibitors Price (US$/Unit) by Application (2019-2030)
 Figure 59. Topoisomerase Inhibitors Value Chain
 Figure 60. Topoisomerase Inhibitors Production Process
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD